Feasibility and pharmacokinetics of nebulized S-ketamine inhalation in healthy adults the NebuKet study

No registrations found.

Ethical review Positive opinion **Status** Recruiting

Health condition type

Study type Interventional

Summary

ID

NL-OMON23977

Source

NTR

Brief title

NebuKet

Health condition

- ketamine
- nebulization
- pharmocokinetics
- analgesia
- side effects

Sponsors and support

Primary sponsor: anesthesiology department of LUMC

Source(s) of monetary or material Support: self-financing research

Intervention

Outcome measures

Primary outcome

safety of procedure

Secondary outcome

analgesia, pharmakinetics ans hemodynamic effects (Blood pressure, cardiac output, heart rate

Study description

Background summary

The aim of this study is to investigate the efficacy and safety of nebulizing S-ketamine. Three different doses of nebulized S-ketamine will be administered. Arterial blood samples will be taken to measure pharmokinetic effect. The analgesic effect will be measured by two different pain tests (pressure and electrical test). Side effects will be evaluated by two questionnaires (Bowdle, and Bond&Lader)

Study objective

- Hypothesis#1 efficacy

We hypothesize that a quick onset, and a predictable dose-response, good adjustability of analgesia can be achieved with inhaled ketamine.

Hypothesis#2 safety

Inhalation of nebulized ketamine might lead to a fast onset of analgesia, with limited adverse events.

Study design

Analgesia:before nebulization, 18, 30, 60 and 80 minutes after start of nebulization, pain relief to pressure pain will be studied

pharmacokinetics: arterial blood samples (3 ml per sample) for ketamine and norketamine will be taken before nebulization/iv infusion and at specific time points during and after inhalation and iv treatment.

- Hemodynamics: Continuous cardiopulmonary monitoring
 - 2 Feasibility and pharmacokinetics of nebulized S-ketamine inhalation in healthy ... 13-05-2025

-Side effects will be inquired before start of nebulization, just after and every 20 minutes after nebulization. Side

effects will be measured using visual analog scales ranging from 0 to 10 cm of the Bowdle and Bond &Lader questionnaires.

Intervention

nebulazing ketamine

Contacts

Public

Leiden University Medical Center (LUMC), Department of Anesthesiology, P.O. Box 9600 Albert Dahan Albinusdreef 2 Leiden 2300 RC The Netherlands +31 (0)71 5262301

Scientific

Leiden University Medical Center (LUMC), Department of Anesthesiology, P.O. Box 9600 Albert Dahan Albinusdreef 2 Leiden 2300 RC The Netherlands +31 (0)71 5262301

Eligibility criteria

Inclusion criteria

men/women 18-39years BMI <30kg/m2

Exclusion criteria

pulmonary disease, hypertensin, liver/renal disease, neurological disorders diaphragmatic hernia/pyrosis, (history of) psychiatric or neurological disease, pregnancy/lactation, allergy to

3 - Feasibility and pharmacokinetics of nebulized S-ketamine inhalation in healthy ... 13-05-2025

study medication, (history of) illicit drug use/alcoholism; concurrent participation in another trial

Study design

Design

Study type: Interventional

Intervention model: Other

Allocation: Non controlled trial

Masking: Open (masking not used)

Control: N/A, unknown

Recruitment

NL

Recruitment status: Recruiting
Start date (anticipated): 12-08-2015

Enrollment: 20

Type: Anticipated

Ethics review

Positive opinion

Date: 11-08-2015

Application type: First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

NTR-new NL5210 NTR-old NTR5358

Other NL53147.058.15: P15.107

Study results